Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation.
Fehse B, Chukhlovin A, Kühlcke K, Marinetz O, Vorwig O, Renges H, Krüger W, Zabelina T, Dudina O, Finckenstein FG, Kröger N, Kabisch H, Hochhaus A, Zander AR. Fehse B, et al. Among authors: zabelina t. J Hematother Stem Cell Res. 2001 Jun;10(3):419-25. doi: 10.1089/152581601750289028. J Hematother Stem Cell Res. 2001. PMID: 11454317
Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Dürken M, Graf von Finkenstein F, Erttmann R, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Zander AR. Kröger N, et al. Among authors: zabelina t. Ann Hematol. 2001 Apr;80(4):209-15. doi: 10.1007/s002770000269. Ann Hematol. 2001. PMID: 11401086
Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow.
Zander AR, Zabelina T, Kröger N, Renges H, Krüger W, Löliger C, Dürken M, Stockschläder M, de Wit M, Wacker-Backhaus G, Bielack S, Jaburg N, Rüssmann B, Erttmann R, Kabisch H. Zander AR, et al. Among authors: zabelina t. Bone Marrow Transplant. 1999 May;23(9):889-93. doi: 10.1038/sj.bmt.1701745. Bone Marrow Transplant. 1999. PMID: 10338043 Clinical Trial.
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR. Kröger N, et al. Among authors: zabelina t. Bone Marrow Transplant. 2000 Oct;26(7):711-6. doi: 10.1038/sj.bmt.1702598. Bone Marrow Transplant. 2000. PMID: 11042650
Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Schäfer P, Hinke A, Zander AR. Kröger N, et al. Among authors: zabelina t. Br J Haematol. 2001 Jun;113(4):1060-71. doi: 10.1046/j.1365-2141.2001.02849.x. Br J Haematol. 2001. PMID: 11442503 Free article.
In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Rischewski J, Sonnenberg S, Ayuk F, Tögel F, Schade U, Fiegel H, Erttmann R, Löliger C, Zander AR. Kröger N, et al. Among authors: zabelina t. Bone Marrow Transplant. 2002 Apr;29(8):683-9. doi: 10.1038/sj.bmt.1703530. Bone Marrow Transplant. 2002. PMID: 12180114
138 results